Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain

Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal Renal Tubular Acidosis (dRTA).

The reimbursed prices of Sibnayal® in Spain are:

- €409.84 including tax for Sibnayal® 24 mEq 847mg/1582 mg

Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain

Other newsrooms on this story

Related reading

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for…

Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of…

Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a…

Sanofi Multiple Sclerosis Drug Gets EU Approval Despite FDA Letter - Sanofi…

Galibra Neuroscience Receives FDA Orphan Drug and Rare Pediatric Disease…

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its…